PARIS, FRANCE / ACCESSWIRE / May 18, 2022 / Abivax SA (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, informs its shareholders that its ordinary and extraordinary general meeting will be held on June 9, 2022, at 10:00 a.m. (CEST), at the offices of Dechert (Paris) LLP, located at 32 rue de Monceau in Paris (75008), France.
The Shareholders' Meeting documents and information and the voting form have been made available to Shareholders under the terms and conditions specified by current French regulations, and are available on the Company's website . All documents are exclusively available in French.
*****
About Abivax (www.abivax.com)
Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at www.abivax.com . Follow us on Twitter @ABIVAX_.
Contacts
Abivax
Communications
Regina Jehle
regina.jehle@abivax.com
+33 6 24 50 69 63
Investors
LifeSci Advisors
Ligia Vela-Reid
lvela-reid@lifesciadvisors.com
+44 7413 825310
Press Relations & Investors Europe
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529 252 22
Public Relations France
Actifin
Ghislaine Gasparetto
ggasparetto@actifin.fr
+33 6 21 10 49 24
Public Relations France
Primatice
Thomas Roborel de Climens
thomasdeclimens@primatice.com
+33 6 78 12 97 95
Public Relations USA
Rooney Partners LLC
Jeanene Timberlake
jtimberlake@rooneypartners.com
+1 646 770 8858
SOURCE: ABIVAX
View source version on accesswire.com:
https://www.accesswire.com/701897/Abivax-Announces-Annual-Ordinary-and-Extraordinary-General-Meeting-on-June-9-2022-and-the-Availability-of-the-Preparatory-Documents
